T. Rowe Price Associates’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$494M Buy
7,873,368
+416,082
+6% +$33.3M 0.06% 253
2025
Q4
$711M Sell
7,457,286
-920,040
-11% -$90.2M 0.08% 196
2025
Q3
$818M Sell
8,377,326
-2,643,954
-24% -$274M 0.09% 187
2025
Q2
$1.18B Buy
11,021,280
+410,793
+4% +$41.6M 0.13% 147
2025
Q1
$1.07B Buy
10,610,487
+1,664,108
+19% +$168M 0.13% 152
2024
Q4
$799M Buy
8,946,379
+695,000
+8% +$61.2M 0.09% 195
2024
Q3
$691M Buy
8,251,379
+180,326
+2% +$14.2M 0.08% 228
2024
Q2
$622M Buy
8,071,053
+888,893
+12% +$65.1M 0.07% 229
2024
Q1
$492M Buy
7,182,160
+878,404
+14% +$56.5M 0.06% 275
2023
Q4
$364M Buy
6,303,756
+516,386
+9% +$27.6M 0.05% 302
2023
Q3
$306M Buy
5,787,370
+1,195,590
+26% +$62.7M 0.04% 318
2023
Q2
$248M Buy
4,591,780
+560,880
+14% +$29.3M 0.03% 359
2023
Q1
$202M Buy
4,030,900
+1,663,351
+70% +$78.4M 0.03% 382
2022
Q4
$110M Buy
2,367,549
+517,236
+28% +$22.4M 0.02% 472
2022
Q3
$71.7M Buy
1,850,313
+7,738
+0.4% +$310K 0.01% 556
2022
Q2
$68.7M Sell
1,842,575
-194,886
-10% -$7.93M 0.01% 780
2022
Q1
$90.2M Sell
2,037,461
-3,778,489
-65% -$164M 0.01% 758
2021
Q4
$247M Sell
5,815,950
-19,329
-0.3% -$812K 0.02% 502
2021
Q3
$253M Sell
5,835,279
-390,328
-6% -$17.3M 0.02% 472
2021
Q2
$266M Sell
6,225,607
-289,028
-4% -$12.2M 0.02% 479
2021
Q1
$252M Sell
6,514,635
-7,747,002
-54% -$293M 0.03% 488
2020
Q4
$513M Sell
14,261,637
-27,915,803
-66% -$1.01B 0.05% 323
2020
Q3
$1.61B Buy
42,177,440
+13,594,354
+48% +$524M 0.19% 114
2020
Q2
$1B Buy
28,583,086
+11,640,875
+69% +$419M 0.13% 170
2020
Q1
$553M Buy
16,942,211
+835,933
+5% +$32.7M 0.09% 242
2019
Q4
$728M Sell
16,106,278
-1,354,314
-8% -$56.7M 0.09% 227
2019
Q3
$710M Buy
17,460,592
+3,711,940
+27% +$157M 0.1% 215
2019
Q2
$591M Buy
13,748,652
+3,039,311
+28% +$117M 0.08% 252
2019
Q1
$411M Buy
10,709,341
+1,593,030
+17% +$60.8M 0.06% 298
2018
Q4
$322M Buy
9,116,311
+1,089,045
+14% +$39.5M 0.05% 318
2018
Q3
$309M Buy
8,027,266
+2,261,008
+39% +$79M 0.05% 380
2018
Q2
$189M Buy
5,766,258
+3,407,385
+144% +$103M 0.03% 493
2018
Q1
$64.4M Sell
2,358,873
-2,303,102
-49% -$62.6M 0.01% 787
2017
Q4
$116M Buy
4,661,975
+2,254,532
+94% +$62.2M 0.02% 593
2017
Q3
$70.2M Sell
2,407,443
-98,245
-4% -$2.71M 0.01% 735
2017
Q2
$69.5M Sell
2,505,688
-46,495
-2% -$1.23M 0.01% 716
2017
Q1
$63.5M Sell
2,552,183
-7,190
-0.3% -$175K 0.01% 726
2016
Q4
$55.4M Sell
2,559,373
-1,900
-0.1% -$41.5K 0.01% 777
2016
Q3
$61M Buy
2,561,273
+57,610
+2% +$1.37M 0.01% 730
2016
Q2
$58.5M Buy
2,503,663
+57,620
+2% +$1.25M 0.01% 723
2016
Q1
$46M Sell
2,446,043
-1,100
-0% -$19.3K 0.01% 797
2015
Q4
$45.1M Buy
2,447,143
+17,100
+0.7% +$306K 0.01% 799
2015
Q3
$39.9M Buy
2,430,043
+72,200
+3% +$1.23M 0.01% 856
2015
Q2
$41.7M Buy
2,357,843
+36,350
+2% +$650K 0.01% 903
2015
Q1
$41.2M Buy
2,321,493
+92,030
+4% +$1.45M 0.01% 898
2014
Q4
$29.5M Sell
2,229,463
-3,094,370
-58% -$39.6M 0.01% 1019
2014
Q3
$62.9M Sell
5,323,833
-23,100
-0.4% -$291K 0.01% 751
2014
Q2
$68.3M Sell
5,346,933
-117,520
-2% -$1.53M 0.01% 757
2014
Q1
$73.9M Buy
5,464,453
+677,000
+14% +$8.89M 0.02% 724
2013
Q4
$57.5M Sell
4,787,453
-8,567,200
-64% -$101M 0.01% 786
2013
Q3
$157M Buy
13,354,653
+3,990,100
+43% +$43.2M 0.04% 465
2013
Q2
$86.8M Buy
+9,364,553
New +$79.4M 0.02% 614

Other funds holding BSX

T. Rowe Price Associates's BSX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Boston Scientific (BSX) stake by 5.6% in Q1 2026, buying an estimated $33.3M and bringing the position to 7,873,368 shares worth $494M. The position accounts for 0.06% of the portfolio, ranked #253.

T. Rowe Price Associates first reported a position in BSX in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.61B in Q3 2020. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • T. Rowe Price Associates held 7,873,368 shares of Boston Scientific worth $494M as of Q1 2026.
  • T. Rowe Price Associates bought 416,082 Boston Scientific shares in Q1 2026, an estimated $33.3M.
  • Boston Scientific made up 0.06% of T. Rowe Price Associates's portfolio in Q1 2026, its #253 holding.
  • T. Rowe Price Associates first reported a position in Boston Scientific in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Boston Scientific position peaked at $1.61B in Q3 2020.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.